Search All UT System Experts

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

Alex M. DePaoli, Linda S. Higgins, Robert R. Henry, Christos Mantzoros, Fredrick L. Dunn

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?'. Together they form a unique fingerprint.

Medicine & Life Sciences